These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

703 related articles for article (PubMed ID: 31706338)

  • 1. Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports.
    Cutrera R; Wolfler A; Picone S; Rossi GA; Gualberti G; Merolla R; Del Vecchio A; Villani A; Midulla F; Dotta A
    Ital J Pediatr; 2019 Nov; 45(1):139. PubMed ID: 31706338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neonatal outcomes following new reimbursement limitations on palivizumab in Italy.
    Belleudi V; Trotta F; Pinnarelli L; Davoli M; Addis A
    Arch Dis Child; 2018 Dec; 103(12):1163-1167. PubMed ID: 30217858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restricted Palivizumab Recommendations and the Impact on RSV Hospitalizations among Infants Born at > 29 Weeks of Gestational Age: An Italian Multicenter Study.
    Priante E; Tavella E; Girardi E; Militello MA; Mardegan V; Maule MM; Dall'Agnola A; Baraldi E; Manzoni P
    Am J Perinatol; 2019 Jul; 36(S 02):S77-S82. PubMed ID: 31238365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the Updated Guidance for Palivizumab Prophylaxis against Respiratory Syncytial Virus Infection: A Single Center Experience.
    Rajah B; Sánchez PJ; Garcia-Maurino C; Leber A; Ramilo O; Mejias A
    J Pediatr; 2017 Feb; 181():183-188.e1. PubMed ID: 27855996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.
    Buckley BC; Roylance D; Mitchell MP; Patel SM; Cannon HE; Dunn JD
    J Manag Care Pharm; 2010; 16(1):15-22. PubMed ID: 20044843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence.
    Capizzi A; Silvestri M; Orsi A; Cutrera R; Rossi GA; Sacco O
    Ital J Pediatr; 2017 Aug; 43(1):71. PubMed ID: 28807039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain.
    Sanchez-Luna M; Burgos-Pol R; Oyagüez I; Figueras-Aloy J; Sánchez-Solís M; Martinón-Torres F; Carbonell-Estrany X
    BMC Infect Dis; 2017 Oct; 17(1):687. PubMed ID: 29041909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increasing Rates of RSV Hospitalization among Preterm Infants: A Decade of Data.
    Kong AM; Winer IH; Zimmerman NM; Diakun D; Bloomfield A; Gonzales T; Fergie J; Goldstein M; Krilov LR
    Am J Perinatol; 2023 Oct; 40(14):1529-1536. PubMed ID: 34704241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the 2014 American Academy of Pediatrics Immunoprophylaxis Policy on the Rate, Severity, and Cost of Respiratory Syncytial Virus Hospitalizations among Preterm Infants.
    Krilov LR; Fergie J; Goldstein M; Brannman L
    Am J Perinatol; 2020 Jan; 37(2):174-183. PubMed ID: 31430818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of RSV-related hospitalization is associated with gestational age in preterm (born at 29-34 wGA) infants without outpatient palivizumab administration.
    Packnett ER; Winer IH; Oladapo A; Wojdyla M
    Hum Vaccin Immunother; 2023 Aug; 19(2):2252289. PubMed ID: 37828711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Respiratory Syncytial Virus Hospitalizations among U.S. Preterm Infants Compared with Term Infants Before and After the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012-2016.
    Goldstein M; Krilov LR; Fergie J; McLaurin KK; Wade SW; Diakun D; Lenhart GM; Bloomfield A; Kong AM
    Am J Perinatol; 2018 Dec; 35(14):1433-1442. PubMed ID: 29920638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.
    Roeckl-Wiedmann I; Liese JG; Grill E; Fischer B; Carr D; Belohradsky BH
    Eur J Pediatr; 2003 Apr; 162(4):237-44. PubMed ID: 12647196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of palivizumab prophylaxis on the frequency of RSV-associated lower respiratory tract infections in preterm infants: determination of the ideal target population for prophylaxis.
    Cetinkaya M; Oral TK; Karatekin S; Cebeci B; Babayigit A; Yesil Y
    Eur J Clin Microbiol Infect Dis; 2017 Sep; 36(9):1629-1634. PubMed ID: 28391538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.
    Joffe S; Ray GT; Escobar GJ; Black SB; Lieu TA
    Pediatrics; 1999 Sep; 104(3 Pt 1):419-27. PubMed ID: 10469764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Respiratory syncytial virus risk factors in late preterm infants.
    Lanari M; Silvestri M; Rossi GA
    J Matern Fetal Neonatal Med; 2009; 22 Suppl 3():102-7. PubMed ID: 19925369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Respiratory Syncytial Virus Disease: Immunoprophylaxis Policy Review and Public Health Concerns in Preterm and Young Infants.
    Staebler S; Blake S
    Policy Polit Nurs Pract; 2021 Feb; 22(1):41-50. PubMed ID: 33050785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-analysis of Withdrawing Immunoprophylaxis for Respiratory Syncytial Virus in Infants Born at 33-35 Weeks Gestational Age in Quebec: A Multicenter Retrospective Study.
    Papenburg J; Saleem M; Teselink J; Li A; Caouette G; Massé É; Lanctôt KL
    Pediatr Infect Dis J; 2020 Aug; 39(8):694-699. PubMed ID: 32379195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of recent New Vaccine Surveillance Network data regarding respiratory syncytial virus hospitalization rates in US preterm infants.
    DeVincenzo JP; Ambrose CS; Makari D; Weiner LB
    Hum Vaccin Immunother; 2016 Apr; 12(4):971-5. PubMed ID: 26889568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the Financial and Health Burden of Infants at Risk for Respiratory Syncytial Virus.
    Blake SM; Tanaka D; Bendz LM; Staebler S; Brandon D
    Adv Neonatal Care; 2017 Aug; 17(4):292-298. PubMed ID: 27926583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.